Sanofi to invest $474M annually on mRNA vaccine R&D

By The Science Advisory Board staff writers

Sanofi will spend approximately 400 million euros ($474 million U.S.) to accelerate the research and development (R&D) of messenger RNA (mRNA) vaccines.

The company will accelerate vaccine work through its newly launched vaccines mRNA Center of Excellence, which will consist of 400 employees from sites in Massachusetts and France working to deliver next-generation mRNA vaccines against unmet diseases.

The teams will focus on R&D, digital, and chemistry, manufacturing and controls (CMC) of mRNA vaccines in both locations. By 2025, Sanofi hopes to have six clinical vaccine candidates.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?